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ESTIMATING COST-EFFECTIVENESS OF DRUGS THAT DELAY
DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS USING
NET BENEFIT REGRESSION MODEL METHODS
Brown MG1, Hoch JS2, MacKinnon-Cameron D1
1Dalhousie University, Halifax, NS, Canada; 2University of Western
Ontario, London, ON, Canada
OBJECTIVE: To demonstrate the feasibility of using Net 
Beneﬁt Regression Model (NBRM) methods to measure cost-
effectiveness (CE) of new drugs that delay disability progression
in multiple sclerosis (MS). Using the net-beneﬁt; t statistic to esti-
mate cost-effectiveness within a regression framework, the
NBRM simpliﬁes statistical work involved in economic evalua-
tion (e.g., avoiding problems associated with ratio statistics) and
also offers useful insights (e.g., exploring the importance of
covariates on the marginal cost-effectiveness of a treatment).
METHODS: A single-period-single-observation-per-person 
ordinary least squares (OLS) NBRM was generalized to a 
multi-period-multi-observation-per-person mixed-effects (ME)
NBRM. Phase I regressions estimate marginal treatment effects,
costs and net beneﬁts. Phase II methods use marginal results to
estimate area-under-the-curve total health outcome, cost, incre-
mental cost effectiveness ratio (ICER) and net beneﬁt (NB) for
each person-with-MS (PwMS) treated and for the treatment
program. DATA: Feasibility was tested using MS Research Unit
person-level clinic-visit observational data, 1980–October 2003:
2296 unique PwMS; 15,589 clinic-visit records; 646 PwMS
treated with new drugs from 1998–2003. Disability progression
is measured by Extended Disability Status Scale (EDSS). Health
outcomes are measured by EDSS-weighted Disability Adjusted
Life Years (DALY) avoided. Clinic data were linked to health ser-
vices utilization and cost data, 1989–2003. RESULTS: Feasibil-
ity of NBRM methods was demonstrated using Nova Scotia
data. The CE for a treatment program and for selected subgroups
of PwMS treated can be estimated using NBRM methods.
Results of a study on the Effectiveness and Cost-Effectiveness of
New MS Drugs in the “Real World” are expected in late 2004.
CONCLUSIONS: It is feasible to apply NBRM methods to
multi-period-multi-observation-per-person data using mixed
effects models. CE estimates derived from person-level observa-
tional data, using NBRM methods, complement CE estimates
derived from group-level observational data, using simulation
model methods.
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COST-EFFECTIVENESS OF MIGRAINE PREVENTION: RESULTS
FROM A MODEL OF TOPIRAMATE TREATMENT
Brown JS1, Papadopoulos G2, Neumann PJ3, Friedman M1, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA; 2Johnson &
Johnson Pharmaceutical Services, Raritan, NJ, USA; 3Harvard School
of Public Health, Boston, MA, USA
OBJECTIVES: Patients whose migraines are frequent, severe,
and/or unresponsive to acute treatment are candidates for
migraine prophylaxis. We developed a cost-effectiveness model
to assess the clinical and economic impact of topiramate treat-
ment versus no prophylaxis for migraine headache. METHODS:
Model inputs included: baseline migraine frequency (6 per
month for the base-case), treatment discontinuation, treatment
response category (>75% reduction in frequency, 50%–75%
reduction in frequency, and <50% reduction in frequency), cost
of prophylaxis (including cost of physician visits for titration),
cost of acute treatment per attack (including pharmacy and
medical service costs), hours of work loss per attack, and hourly
wage. Model outcomes were expressed monthly and included the
number of migraines averted, disability hours, the total cost 
of acute and prophylactic treatment, and lost wages. Costs 
are expressed in 2002 $US. Data for the model were gathered
from published literature and three randomized, double-blinded,
placebo-controlled studies of topiramate in migraine prevention.
We also conducted sensitivity analyses. RESULTS: Topiramate
treatment (dose titrated to a maximum of 100mg/day) was asso-
ciated with a mean reduction in migraine frequency of 1.68 per
month and almost 5 fewer hours of disability. The monthly cost
of prophylaxis was $113. Monthly acute treatment cost was $25
lower for treated patients ($60 versus $85) and work loss was
$46 lower ($118 versus $164). Consequently, in the base-case
assessment, the incremental cost per migraine averted was $26.
The results are sensitive to the baseline migraine rate; as the base-
line migraine rate increases, the total cost of care decreases, with
a break-even point between 9 and 10 migraines per month.
CONCLUSION: Economic savings associated with lower
migraine frequency offset approximately 63% of the cost of 
prophylaxis. The ultimate cost-effectiveness of topiramate will
depend on the gains in utility associated with fewer migraine
episodes, the subject of ongoing research.
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MEDICAL SERVICES UTILIZATION FOR PATIENTS WITH
PARKINSON’S DISEASE IN A STATE MEDICAID PROGRAM
Kamat S, Smith MJ
West Virginia University, Morgantown, WV, USA
Parkinson’s disease (PD), a neurological syndrome characterized
by resting tremors, muscle rigidity, postural instability and
bradykinesia, affects nearly 1 million people in the United States.
Few studies have investigated the costs for health care services
related to this disease. OBJECTIVE: To report the utilization and
costs for medical services and prescription medications for PD
in a state Medicaid population. METHODS: Medicaid adminis-
trative claims dated from January 1, 2002 through December 31,
2002 for medical services (hospitalizations, emergency depart-
ment visits, outpatient visits, and nursing home admissions) with
a primary or secondary ICD-9 diagnosis code for PD were
extracted. Unique and anonymous recipient codes from these
claims were used to extract prescription claims for drugs used
for palliative treatment of PD. Costs reported were from the per-
spective of Medicaid. RESULTS: There were 11,919 recipients
identiﬁed with PD. Of these, a total of 11,785 (99%) recipients
had claims for nursing home care. The average length of stay in
the nursing home was 222 days with an average cost of $27,950
per stay. Only 618 recipients (5%) had claims for an outpatient
visit related to PD, and there were very few ED and hospital visits
for PD. Outpatient prescription costs for drugs related to PD
totaled $501,941, with an average cost of $63 per prescription.
Carbidopa/levodopa (62.5%), pramipexole (8%), and ropinirole
(4%) accounted for the majority of prescriptions dispensed. The
costs for these drugs were $269,020 for carbidopa/levodopa,
$91,359 for pramipexole, and $33,920 for ropinirole. CON-
CLUSION: Among recipients covered by Medicaid, a majority
of health care services utilized for the treatment of PD were for
nursing home care followed by prescription medications. The
results indicated that long-term care and palliative drug treat-
ment were the major contributors of total dollars spent by 
Medicaid for care of its recipients with PD.
